Success Story: Overcoming an RFE to Achieve Success: NAILG Achieves NIW Approval for Researcher Advancing Cancer Treatment Innovation
Client’s Testimonial:
“Thank you very much for your dedicated work.”
On January 11th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Researcher in the field of Medical Science (Approval Notice).
General Field: Medical Science
Position at the Time of Case Filing: Researcher
Country of Origin: Vietnam
Country of Residence at the Time of Filing: Japan
Approval Notice Date: January 11th, 2025
Processing Time: 9 months, 27 days (Premium Processing Requested)
Case Summary:
A talented medical scientist has secured EB-2 NIW (National Interest Waiver) approval with the assistance of NAILG after overcoming a Request for Evidence (RFE). Her work focuses on investigating molecular pathways involved in tumor proliferation, aiming to develop targeted inhibitors and antibodies that can slow or prevent cancer progression. This approval, received after 9 months and 27 days of processing, reflects both the significance of her contributions and NAILG’s strong legal strategy in addressing the government’s concerns with clarity and precision.
Pioneering Cancer Research with National Impact
The petitioner, holding a Ph.D. in Medical Science, has built her career around uncovering the cellular and molecular mechanisms that drive cancer development. By analyzing immune cell mutations and their role in tumor growth, her research has contributed to the development of targeted therapies designed to improve the survival and quality of life of cancer patients. Her findings not only advance scientific understanding but also align with national priorities for precision medicine and cost-effective healthcare innovation in the United States.
Academic Achievements and Research Influence
The petitioner has authored six peer-reviewed journal articles (including three as first author) and one abstract, which together have been cited 42 times by independent researchers. Notably, two of her papers rank among the top 10% most-cited publications in clinical medicine for their respective years, underscoring her influence in the global medical research community.
Contributions Recognized by the Scientific Community
Her investigations into immune cells and markers in stem cell transplantation have provided new insights into cancer progression and treatment resistance. Through these studies, she has revealed molecular mechanisms that could inform the design of next-generation cancer therapies and improve patient monitoring in clinical settings. As one expert stated:
“[Client]’s work has been especially important to the continued development of cancer treatments around the world.”
Research Supported by Prestigious Institutions
The significance of her work is further validated by funding from leading organizations such as the Japan Agency for Medical Research and Development (AMED), Grants-in-Aid for Scientific Research, the MSD Life Science Foundation, and the Princess Takamatsu Cancer Research Fund, among others. These competitive grants highlight the high regard for her contributions within the international scientific community and their relevance to advancing public health.
NIW Approval and Outlook
This NIW approval, achieved despite the issuance of an RFE, demonstrates NAILG’s ability to craft persuasive, evidence-based responses that effectively address USCIS inquiries. Through this petition, NAILG underscored the petitioner’s vital role in advancing cancer research and her capacity to contribute meaningfully to U.S. medical innovation. Her continuing work on tumor biology and targeted therapies is expected to further support national goals in biomedical research and cancer care, reflecting both her dedication and NAILG’s commitment to championing scientists whose research carries global impact.